錦欣生殖(1951.HK)拉漲近12% 股價創歷史新高
格隆匯12月16日丨錦欣生殖(1951.HK)盤中拉昇漲11.71%至15.26港元,股價突破2019年11月創出的歷史高點再創新高,市值超370億港元。廣發證券近日發研報給予其買入評級,廣發證券指出:公司收購武漢錦欣,IPO後首個國內併購標的落地,目前武漢錦欣已吸引全國著名試管嬰兒專家楊菁教授加入,將助力錦欣武漢快速打造優質的醫生團隊,實現週期數的快速攀升;同時,公司整合國際業務渠道商夢美,繼續加強國際業務能力,有助於公司進一步整合資源及提升業內領先地位。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.